Enzyvant Sciences Ltd.

About Enzyvant Sciences Ltd.

Enzyvant is a new biopharmaceutical company formed by Roivant Sciences and Plexcera Therapeutics focused on the treatment of patients with Farber disease, a rare lysosomal storage disease. Enzyvant is completing pre-clinical studies for recombinant human acid ceramidase (rhAC), an enzyme replacement therapy, to enable a clinical trial in patients with Farber disease.
CEO: Alvin Shih

20 articles with Enzyvant Sciences Ltd.